Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini
Maria Rosaria
MR
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib
Am J Obstet Gynecol. 2006 Apr;194(4):1203; author reply 1204
16580341
J Clin Oncol. 2006 May 1;24(13):1997-2005
16648500
JAMA. 2006 Jun 7;295(21):2516-24
16757724
Curr Oncol Rep. 2007 Mar;9(2):85-6
17288871